Though Trump took a national abortion ban off the table, they’re still pushing to restrict abortion pills via FDA and EPA regulations.

The House is up at bat after the Senate’s failure last week to pass either Democrats’ multi-year clean extension of the health insurance subsidies or Republicans’ alternative plan that would have funneled money into health savings accounts and imposed new national restrictions on abortion and gender-affirming care.

Two state lawmakers are sparring over how to enshrine protections in state law for women who have miscarriages or other pregnancy complications

The Food and Drug Administration has delayed a promised review of safety data for the abortion drug mifepristone at Commissioner Marty Makary’s request to put it off until after the midterm elections,

Following a pressure campaign from anti-abortion groups, Makary and Health and Human Services Secretary Robert F. Kennedy Jr. announced in June that they would conduct a new assessment of mifepristone despite the drug’s 25-year safety record.

Marjorie Dannenfelser called for FDA Commissioner Marty Makary to be fired for allegedly delaying a mifepristone safety review.